Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

[1]  A. Annalisa,et al.  Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature , 2017, Leukemia research reports.

[2]  G. Guyatt,et al.  GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. , 2016, Journal of clinical epidemiology.

[3]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[4]  R. Champlin,et al.  Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[6]  R. Emerson,et al.  A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study , 2015, Leukemia.

[7]  S. Stilgenbauer.  Prognostic markers and standard management of chronic lymphocytic leukemia. , 2015, Hematology. American Society of Hematology. Education Program.

[8]  A. Bagg,et al.  Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. , 2015, Cancer genetics.

[9]  B. Djulbegovic,et al.  High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review , 2015, Bone Marrow Transplantation.

[10]  D. Porter,et al.  A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. , 2015, Blood.

[11]  Jeffrey A Jones,et al.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[12]  Jeffrey A Jones,et al.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.

[13]  Susan O'Brien,et al.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. , 2015, Blood.

[14]  P. Fox,et al.  Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis , 2015, Leukemia & lymphoma.

[15]  Thomas E. Hughes,et al.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[16]  M. Perales,et al.  Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Kimby,et al.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? , 2014, Blood.

[18]  H. Döhner,et al.  Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation , 2014, American journal of hematology.

[19]  A. Rosenwald,et al.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.

[20]  J. Byrd,et al.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.

[21]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[22]  T. Shanafelt,et al.  How we treat Richter syndrome. , 2014, Blood.

[23]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[24]  W. Wierda,et al.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors , 2014, Leukemia.

[25]  C. Carlo-Stella,et al.  Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis , 2014, Bone Marrow Transplantation.

[26]  T. Habermann,et al.  Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients , 2013, British journal of haematology.

[27]  Jennifer R. Brown.  Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future , 2013, Therapeutic advances in hematology.

[28]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[29]  N. Schmitz,et al.  TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. , 2013, Blood.

[30]  A. Pettitt,et al.  Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia , 2012, British journal of haematology.

[31]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[32]  B. Djulbegovic,et al.  Successful allogeneic cord blood transplantation in a patient with Evans syndrome leads to correction of hereditary angioedema type I as secondary effect , 2012, Bone Marrow Transplantation.

[33]  J. Byrd,et al.  Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Feugier,et al.  Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial , 2012, Bone Marrow Transplantation.

[35]  P. Rohrlich,et al.  Systematic donor blood qualification by flow cytometry would have been able to avoid CLL‐type MBL transmission after unrelated hematopoietic stem cell transplantation , 2012, European journal of haematology.

[36]  N. Chiorazzi,et al.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.

[37]  L. Pecciarini,et al.  General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. , 2011, Blood.

[38]  M. Keating,et al.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.

[39]  L. Larocca,et al.  Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis , 2011, International journal of cancer.

[40]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[41]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[42]  S. Leprêtre,et al.  Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. , 2011, Blood.

[43]  G. Guyatt,et al.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. , 2011, Journal of clinical epidemiology.

[44]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[45]  S. Pileri,et al.  The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. , 2011, Blood.

[46]  R. Brand,et al.  Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. , 2011, Blood.

[47]  M. Dyer,et al.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Foà,et al.  Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. , 2009, Blood.

[49]  Marcos González,et al.  Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. , 2009, Blood.

[50]  M. Björkholm,et al.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin’s lymphomas among relatives of patients with chronic lymphocytic leukemia , 2009, Haematologica.

[51]  T. Braun,et al.  Reduced intensity versus full myeloablative stem cell transplant for advanced CLL , 2009, Bone Marrow Transplantation.

[52]  H. Kantarjian,et al.  Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia , 2009, Cancer.

[53]  N. Schmitz,et al.  Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Ho,et al.  Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML , 2008, Bone Marrow Transplantation.

[55]  J. Pinilla-Ibarz,et al.  Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia , 2008, Cancer.

[56]  S. Richards,et al.  Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. , 2008, The New England journal of medicine.

[57]  Davide Rossi,et al.  Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome , 2008, British journal of haematology.

[58]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[59]  A. Dispenzieri,et al.  Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years , 2008, Leukemia & lymphoma.

[60]  G. Marti,et al.  Bioethical considerations of monoclonal B‐cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation , 2007, British journal of haematology.

[61]  A. Rosenwald,et al.  IgVH Mutational Status and Clonality Analysis of Richter's Transformation: Diffuse Large B-cell Lymphoma and Hodgkin Lymphoma in Association With B-cell Chronic Lymphocytic Leukemia (B-CLL) Represent 2 Different Pathways of Disease Evolution , 2007, The American journal of surgical pathology.

[62]  C. Bueso-Ramos,et al.  Graft‐versus‐leukaemia effect after non‐myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP‐70 in refractory chronic lymphocytic leukaemia , 2007, British journal of haematology.

[63]  J. Byrd,et al.  International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.

[64]  J. Lipton,et al.  Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease , 2005, Bone Marrow Transplantation.

[65]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[66]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[67]  F. Appelbaum,et al.  Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia , 2002, Bone Marrow Transplantation.

[68]  L. Ross,et al.  Are doctors altruistic? , 2002, Journal of medical ethics.

[69]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[70]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[71]  J. Pinilla-Ibarz,et al.  Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single‐Center Experience , 2018, Clinical lymphoma, myeloma & leukemia.

[72]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[73]  M. Görner,et al.  The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  A. Bazarbachi,et al.  Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[75]  E. Kimby,et al.  Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.

[76]  G. Marti,et al.  Genetically identical twin transplantation for chronic lymphocytic leukemia , 2007, Leukemia.